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Phosphatidylinositol 3-kinase
Tyrosine kinasePhosphatidylinositol 3-kinaseβ (PI3Kβ) plays a predominant role in integrin outside-in signaling and in platelet
activation by GPVI engagement. We have shown that the tyrosine kinase Pyk2 mediates PI3Kβ activation down-
streamof integrinαIIbβ3, and promotes the phosphorylation of the PI3K-associated adaptor protein c-Cbl. In this
study,we compared the functional correlation between Pyk2 and PI3Kβ upon recruitment of the twomain plate-
let collagen receptors, integrin α2β1 and GPVI. PI3Kβ-mediated phosphorylation of Akt was inhibited in Pyk2-
deﬁcient platelets adherent to monomeric collagen through integrinα2β1, but occurred normally upon GPVI li-
gation. Integrin α2β1 engagement led to Pyk2-independent association of c-Cbl with PI3K. However, c-Cbl was
not phosphorylated in adherent platelets, and phosphorylation of Akt occurred normally in c-Cbl-deﬁcient plate-
lets, indicating that the c-Cbl is dispensable for Pyk2-mediated PI3Kβ activation. Stimulation of platelets with
CRP, a selective GPVI ligand, induced c-Cbl phosphorylation in the absence of Pyk2, but failed to promote its as-
sociationwith PI3K. Pyk2 activationwas completely abrogated in PI3KβKD, but not in PI3KγKDplatelets, andwas
strongly inhibited by Src kinases and phospholipase C inhibitors, and by BAPTA-AM. The absence of PI3Kβ activ-
ity also hampered GPVI-induced tyrosine–phosphorylation and activation of PLCγ2, preventing intracellu-
lar Ca2+ increase and phosphorylation of pleckstrin. Moreover, GPVI-induced intracellular Ca2+ increase
and pleckstrin phosphorylation were also strongly inhibited in human platelets treated with the PI3Kβ in-
hibitor TGX-221. These results outline important differences in the regulation of PI3Kβ by GPVI and integrin
α2β1 and suggest that inhibition of Pyk2 may target PI3Kβ activation in a selective context of platelet
stimulation.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Blood platelets are activated by a multitude of extracellular factors
that trigger shape change, secretion and aggregation by stimulating
different classes of membrane receptors, including G-proteins–coupled
receptors, integrins and platelet speciﬁc glycoproteins such as GPVI
and the GPIb-IX-V complex [1]. The intracellular signaling pathwaysd Biotechnology, Laboratory of
a, Italy. Tel.: +39 0382 987238;
hungbuk National University,stimulated downstream of the different platelet receptors display unique
features, but they also share a number of key events. In particular, stimu-
lation of two phosphoinositide-metabolizing enzymes, phospholipase C
(PLC) and phosphatidylinositol 3-kinase (PI3K) occurs in all the contexts
of platelet activation, and thus these enzymes represent crucialmediators
of the platelet response.
The mechanism for PLC activation downstream of the different plate-
let receptors is quite understood:members of the PLCβ subfamily, namely
PLCβ2 and PLCβ3 are stimulated by binding of α subunits (αq and α11)
or βγ dimers of activated G proteins upon stimulation of PAR1 and
PAR4 by thrombin, P2Y1 receptor by ADP, or TPα receptor by thrombox-
ane A2 [2,3]. Alternatively, integrin ligation by adhesive proteins, interac-
tion of von Willebrand Factor with GPIb-IX-V, or recruitment of ITAM-
bearing receptors, such as GPVI, CLEC-2 and FcγRIIa, stimulates the
PLCγ2 isoform by direct phosphorylation, and through the contribution
of 3-phosphoinositides and the small GTPase Rac [4–6].
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lets is still poorly characterized. All four members of class I PI3K, that
are responsible for the synthesis of phosphatidylinositol 3,4,5-trisphos-
phate (PtdIns(3,4,5)P3), are expressed in platelets but they contribute
differently to platelet activation [7]. While the class IB isoform PI3Kγ
appears to be activated downstream of G-proteins–coupled receptors
[8], a number of pharmacological and genetic evidence indicates that
the class IA member PI3Kβ plays a predominant role in platelet activa-
tion, being involved not only downstreamof G-proteins–coupled recep-
tors, but also upon integrins and ITAM-bearing receptors stimulation
[9–11]. The roles of PI3Kδ and PI3Kα are minor or still controversial
[12,13].
Class IA PI3K members are heterodimers composed of a 110 kDa
catalytic subunit and a p85 regulatory subunit, which keeps the en-
zyme in an inactive state [14]. As with other members of its class,
PI3Kβ is generally considered to be activated upon binding of tyro-
sine phosphorylated proteins to the regulatory subunit p85, which
overcomes the constitutive inhibitory effect. In a recent study we
have demonstrated that integrin αIIbβ3 ligation in ﬁbrinogen–ad-
herent platelets induces the association of the adaptor protein c-
Cbl with the p85 regulatory subunit of PI3K through its SH3 domain,
and that p85-associated c-Cbl is subsequently tyrosine phosphory-
lated by the focal adhesion kinase Pyk2 [15], suggesting a possible
mechanism of PI3Kβ activation and Akt phosphorylation. It is
known that PI3Kβ is also activated downstream of the collagen re-
ceptors integrin α2β1 and GPVI [9,10,16]. Moreover, integrin
α2β1-triggered phosphorylation of Akt was reduced in platelets
from Pyk2 knockout mice [16].
Based on this background,wehypothesized that phosphorylation of c-
Cbl by Pyk2 and the interaction of c-Cbl with the p85 subunit could
represent a general strategy for PI3Kβ regulation in platelets. In the
present study, we compared the mechanism for PI3Kβ stimulation by
the two main collagen receptors in platelets, integrin α2β1 and GPVI.
We found that Pyk2 regulation of PI3Kβ is restricted to integrin signaling
and does not operate upon GPVI stimulation where, in contrast, Pyk2 is
downstream of PI3Kβ. Moreover, we found that phosphorylation of c-
Cbl is dispensable for both Pyk2-dependent and -independent regulation
of PI3Kβ by the platelet collagen receptors.2. Materials and methods
2.1. Materials
PI3KβKD, PI3KγKD, Pyk2 and c-Cbl knockout mice were generat-
ed and characterized as reported elsewhere [17–20]. The use of
mice for our experimental work was approved by the Ethics Com-
mittee of the University of Pavia. Monomeric type I collagen was
provided by Prof. M.E. Tira (University of Pavia, Italy). Convulxin
was from Centerchem, Inc. (Norwalk, CT, USA).and collagen-
related peptide (CRP) was provided by Dr. R. Farndale (University
of Cambridge, UK). The rabbit polyclonal antibodies against Pyk2
(N-19), as well as the mouse monoclonal antibody anti-tubulin
(DM1A) were from Santa Cruz Biotechnology (Tebu-Bio, Magenta,
Italy). Anti-phosphoPyk2(Tyr402), anti-phosphoAkt(Ser473),
anti-phosphoAkt(Thr308), and anti-phospho(Ser) PKC substrates,
anti-phosphoSyk(Tyr525/526), anti-Akt, and anti β-actin anti-
bodies were from Cell Signaling Technology (Celbio, Pero, Italy).
Anti-phosphotyrosine (Clone 4G10) and anti-PI3 kinase(p85) an-
tibodies were from Millipore (Prodotti Gianni, Milano, Italy). Anti
c-Cbl monoclonal antibodies was from BD Biosciences (Milano, Italy).
Anti-pleckstrinwas fromAbcam (Prodotti Gianni, Milano, Italy). Appro-
priate peroxidase-conjugated anti-IgG antibodies were from Bio-Rad
(Milan, Italy). BAPTA-AM, U73122, PP2, wortmannin, AS252424 and
TGX-221 were from Alexis Biochemicals (3VChimica, Roma, Italy).
Fura-2-AM was from Calbiochem (VWR, Milano, Italy).2.2. Preparation of washed mouse platelets
Blood platelets preparation from wild type and transgenic mice
was performed essentially as previously described [21] according
to a protocol approved by the Ethics Committee of the University
of Pavia. Animals were anesthetized, and blood was withdrawn
from the abdominal vena cava using ACD/3.8% sodium citrate (2:1)
as anticoagulant. Anticoagulated blood was diluted with HEPES
buffer (10 mM HEPES, 137 mM NaCl, 2.9 mM KCl, 12 mM NaHCO3,
pH 7.4) up to 2 ml and centrifuged for 10 min at 180 g to obtain
platelet-rich-plasma (PRP). PRP was then transferred to new tubes
and the remaining red blood cells were diluted with HEPES buffer
to a ﬁnal volume of 2 ml and centrifuged again at 180 g for 7 min.
The upper phase was added to the previously collected PRP, and
0.02 U/ml apyrase plus 1 μM PGE1 were added before centrifugation
at 550 g for 10 min. Platelets were washed with 1 ml PIPES buffer
(20 mM PIPES, 136 mM NaCl, pH 6.5), and ﬁnally resuspended in
HEPES buffer.
2.3. Platelet adhesion and stimulation
Washedmurine plateletswere ﬁnally resuspended at 0.3× 109 cells/
ml and, upon addition of 5.5 mM glucose, cells were allowed to rest for
30 min at room temperature.
Polystyrene dishes (60-mm) were coated overnight at room tem-
perature with 50 μg/ml monomeric type I collagen diluted in 0.1 M
acetic acid. Dishes were washed 3 times with 5 ml PBS, blocked with
2 ml 1% BSA in PBS for 2 h at room temperature, and then washed again
3 times with PBS. Murine platelets (0.5 ml) were added to collagen-
coated dishes in the presence of 2 mMMgCl2 and 1 mg/ml BSA. Apyrase
(0.4 U/ml) was also typically added to the platelet suspension, as indicat-
ed in the text. After 30 or 60min of incubation at room temperature, non-
adherent cells were removed, and dishes were washed 3 times with 5ml
PBS. Forwhole cell lysate preparation, adherent cellswere directly solubi-
lized by addition of 0.5 ml of 2% SDS in HEPES buffer, and then collected.
For immunoprecipitation experiments, cells were lysed with 0.3 ml ice-
cold immunoprecipitation buffer (20 mM Tris/HCl pH 7.4, 100 mM
NaCl, 0.2% Nonidet P-40, 1 mM PMSF, 10 μg/ml leupeptin, 10 μg/ml
aprotinin, 1 mM Na3VO4). Lysates were centrifuged at 18,000 g for
10 min, and the protein content in the cleared supernatant was deter-
mined by the bicinchoninic acid assay. Aliquots of each sample containing
the same amount of proteins (and, thus, deriving from the same number
of adherent platelets) were used for further analysis.
Stimulation of platelets in suspension (0.3 × 109 cells/ml, 400 μl)
was typically performed with 0.5 μg/ml CRP at 37 °C under constant
stirring. Platelet lysis for subsequent analysis was performed by addition
of an equal volume of 2% SDS inHEPES buffer or 2× immunoprecipitation
buffer.
2.4. Immunoprecipitation
For immunoprecipitation experiments, lysates of resting or stimulat-
ed, non adherent or adherent platelets containing equal amount of pro-
teins, were incubated with 0.8 μl whole antiserum anti-PI3 kinase(p85)
or with 1 μg anti-c-Cbl for 2 h at 4 °C, and then 80 μl protein A-
Sepharose (50 mg/ml stock solution) or 80 μl protein G–Sepharose, re-
spectively, were added. Immunoprecipitates were recovered, washed
and ﬁnally resuspended with 25 μl SDS-sample buffer (25 mM Tris,
192 mM glycine, 2% SDS, 0.5% DTT, 10% glycerol, 0.01% bromophenol
blue, pH 8.3), as previously described [22].
2.5. Electrophoresis and immunoblotting
Aliquots of platelet lysates containing the same amount of proteins, or
immunoprecipitated proteins were separated by SDS-PAGE, typically on
7.5% acrylamide gels, and proteins were transferred to PVDF membrane.
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NaCl),membranes were incubated overnight at 4 °C with the desired
primary antibodies diluted in TBS. In the present study the following
antibodies and dilution were used: anti-phosphoAkt(Ser473), anti-
phosphoAkt(Thr308), 1:500; anti-phosphoPyk2(Tyr402), 1:500;
anti-tubulin, 1:1000; anti-Akt, 1:1000; anti-Pyk2, 1:500; anti-
phosphoTyr, 1:1000; anti-PI3 kinase(p85), 1:1000; anti-c-Cbl,
1:1000; anti-phospho(Ser) PKC substrates antibodies, 1:1000; and
anti-pleckstrin 1:1000. Membranes were washed, incubated withFig. 1. Pyk2, but not c-Cbl,mediates PI3Kβ activation by integrinα2β1. Platelets fromwild type (
or 60 min. Adherent cells, as well as samples of non-adherent cells (NA) at 60 min, were collec
blotting with speciﬁc phospho-antibodies as indicated. A representative immunoblot is shown
loading. Histograms in (ii) and (iii) report the quantitative analysis of Akt phosphorylation on
bars). Data are the mean ± SD of three different experiments. (B) The p85 regulatory subuni
wild type (WT) and Pyk2 KOmice. Lysates of adherent platelets were also immunoprecipitated
with anti-c-Cbl, followed by reprobing with anti-p85 antibodies, as indicated on the right. The r
parable results. (C) c-Cblwas immunoprecipitated frommurine (i) or human (ii) platelets adher
fromuntreated (BAS) or CRP-stimulated platelets (CRP 0.5 μg/ml, 1min). Immunoblotting analy
Cbl antibody. An immunoblot representative of three similar experiments is reported. (D) P
immobilized monomeric collagen or to bovine serum albumin (BSA) for 45 min. Analysis of Ak
bodies. Phosphorylated Syk(Tyr525/526), Akt(Ser473), and Akt(Thr308) are indicated by the a
anti β-actin was performed as control for equal loading. Quantitative analysis of protein phosph
p b 0.005.appropriate peroxidase-conjugated secondary antibody (1:3000 dilu-
tion), and proteins were visualized with a chemiluminescence reaction,
as described [23]. Typically, the PVDFmembranes were treated with 1%
NaN3 in TBS for 4 h at room temperature and reprobed with a different
antibody as a control for equal loading. All the experiments reported in
this study were repeated at least three times, and comparable results
were obtained. The blots reported in the ﬁgures are representative im-
ages.When the observed differences deserved to be quantiﬁed, analysis
of band intensity was performed by computer assisted densitometricWT) andPyk2 KOmicewere allowed to adhere to immobilizedmonomeric collagen for 30
ted and lysed. (A) Akt phosphorylation on Ser473 and Thr308 was analyzed by immuno-
in (i), where reprobing with anti-Akt (lower panel) was performed as control for equal
Ser473 and Thr308, respectively, in wild type (black bars) and Pyk2 KO platelets (grey
t of PI3K was immunoprecipitated from adherent and non-adherent platelets (NA) from
with a non-related antibody (NR Ab), as control. Immunoblotting analysis was performed
eported immunoblot is representative of three different experiments that produced com-
ent tomonomeric collagen for 30 or 60min. As control, c-Cblwas also immunoprecipitated
siswas performedwith anti-phosphotyrosine antibody, followed by reprobingwith anti c-
latelets from wild type (WT) and c-Cbl KO (cCbl−/−) mice were allowed to adhere to
t and Syk phosphorylation was performed by immunoblotting with phosphospeciﬁc anti-
rrows on the left in the representative immunoblot reported in (i). Immunoblotting with
orylation is reported in (ii) as mean± SD of three different experiments. * = p b 0.05; ***
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with the Student t-test.2.6. Measurement of cytosolic Ca2+ concentration
Intracellular Ca2+ concentration was measured in Fura-2-AM loaded
platelets essentially as previously described [24]. Brieﬂy, human or
mouse platelets in PRP were incubated with 3 μM Fura-2-AM for
40min at 37 °C in the dark. Apyrase and PGE1were then added and plate-
lets were recovered by centrifugation, washed with PIPES buffer, and
ﬁnally resuspended inHEPES buffer containing 0.5% BSA. For these exper-
iments, the ﬁnal platelet concentration was adjusted to 2 × 108 cells/ml,
and stimulation was performed at 37 °C on 0.4 ml samples under gentleFig. 2.GPVI-induced activation of PI3Kβ is independent of Pyk2. (A) Platelets fromwild type (WT)
lysates were prepared. Immunoblotting analysis was performed with antibodies against pAkt(Ser
immunoblot is reported,while panels (ii) and (iii) show the quantiﬁcation of Akt phosphorylation
the mean± SD of three different experiments. ***, p b 0.005. (B) Platelets fromwild type (WT) an
munoblotting with antibodies against Pyk2, pAkt(Ser473), pAkt(Thr308), or Akt, as indicated on t
ylation on Ser473 and Thr308 inwild type (black bars) and PI3KβKD (gray bars) platelets is report
p b 0.005. (C) Polystyrene dishes were coated overnight with 20 μg/ml CRP, and wild type (WT)
adherent, as well as non-adherent (NA), platelets were lysated and analyzed by immunoblott
Immunoblotting with anti-Akt antibody conﬁrmed that comparable amounts of proteins were lo
(black bars) and PI3KβKD (gray bars) platelets is reported in (ii) and (iii), respectively. Results arstirring in a PerkinElmer Life Sciences LS3 spectroﬂuorometer in the
presence of 1 mM EGTA.3. Results
3.1. The role of Pyk2 and c-Cbl in PI3Kβ activation downstream of integrin
α2β1
We have recently demonstrated that the tyrosine kinase Pyk2 is
required for PI3Kβ activation downstream of integrin αIIbβ3, and that
the adaptor protein c-Cbl is phosphorylated by Pyk2, which then associ-
ateswith the p85 regulatory subunit of PI3K [15]. The present studywas
aimed to investigate whether this pathway represents a recurrentand PI3KβKDmicewere stimulatedwith 0.5 μg/ml CRP for the indicated times, andwhole cell
473) and pAkt(Thr308) or against Akt for equal loading control. In panel (i) a representative
on Ser473 and Thr308 inwild type (black bars) and PI3KβKD (gray bars) platelets. Results are
d Pyk2 KOmice stimulated with 0.5 μg/ml CRP for the indicated times were analyzed by im-
he right. A representative immunoblot is reported in (i), and quantiﬁcation of Akt phosphor-
ed in (ii) and (iii), respectively. Results are themean± SD of three different experiments. ***,
or Pyk2-deﬁcient (Pyk2KO) platelets were allowed to adhere for 30 and 60 min. Samples of
ing for Akt phosphorylation on Ser473 and Thr308, as indicated on the right in panel (i).
aded in each lane. Quantiﬁcation of Akt phosphorylation on Ser473 and Thr308 in wild type
e the mean ± SD of three different experiments.
1883D. Manganaro et al. / Biochimica et Biophysica Acta 1853 (2015) 1879–1888strategy for PI3Kβ activation in platelets. It is known that PI3Kβ is also
stimulated upon platelet adhesion to speciﬁc ligands of integrin α2β1,
such as the GFOGER peptide or monomeric collagen, and that integrin
α2β1-induced Akt phosphorylation on Ser473 is impaired in platelets
lacking Pyk2 [9,10,16]. To further investigate the mechanism linking
Pyk2 to PI3Kβ activation, we analyzed Akt phosphorylation in platelets
from wild type and Pyk2 knockout mice adherent to monomeric type I
collagen, under conditions that have been previously demonstrated to
recruit exclusively integrin α2β1 [6,25]. In agreement with previous
ﬁndings, we conﬁrmed the importance of Pyk2 for PI3Kβ activation, as
Akt phosphorylation on both Ser473 and Thr308was reduced, although
not completely abrogated, in the absence of Pyk2 (Fig. 1A). To investi-
gate the possible involvement of c-Cbl in Pyk2-mediated activation of
PI3Kβ downstream of integrin α2β1, the p85 regulatory subunit was
immunoprecipitated from platelets adherent to monomeric collagen,
as well as from non-adherent cells. The presence of c-Cbl in the immu-
noprecipitates was investigated by immunoblotting. Fig. 1B shows that
platelet adhesion through integrinα2β1 caused the association of c-Cbl
to the p85 subunit both in wild-type and in Pyk2-deﬁcient platelets. To
verify whether c-Cbl is actually tyrosine phosphorylated upon integrin
α2β1 recruitment, the protein was directly immunoprecipitated from
murine platelets adherent to monomeric collagen and analyzed by
immunoblotting with the anti-phosphotyrosine antibody. Surprisingly
we found that integrinα2β1 engagement failed to induce c-Cbl tyrosine
phosphorylation, which was clearly detected upon stimulation with
CRP (Fig. 1C). The inability of integrin α2β1 to induce c-Cbl tyrosine
phosphorylation was not restricted to murine platelets, as it was also
conﬁrmed using human platelets adherent to monomeric collagen
(Fig. 1C). Since this observation argues against a role of c-Cbl phosphor-
ylation in integrin α2β1-induced PI3Kβ activation, we analyzed Akt
phosphorylation in platelets from c-Cbl knockout mice. Fig. 1D shows
that platelet adhesion to monomeric collagen caused phosphorylation
of Akt on Ser473 and Thr308 both in wild type and c-Cbl-deﬁcientFig. 3. c-Cbl is not involved in PI3Kβ activation downstreamof GPVI. (A)Wild type (WT) and Pyk
c-Cblwas immunoprecipitatedwith a speciﬁc antibody, and its phosphorylationwas evaluated b
was then reprobed with anti c-Cbl antibody (lower panel) to verify the efﬁciency of the immun
iments is reported in panel (ii): black bars: wild type platelets; grey bar: Pyk2KO platelets. Data
Pyk2KO mice were stimulated with 0.5 μg/ml CRP for the indicated times, and the p85
immunoprecipitated from wild type platelets adherent to immobilized ﬁbrinogen. Immunob
the right. The reported image is representative of three different experiments producing iden
type (WT) and c-Cbl-deﬁcient (cCbl−/−) platelets stimulated with the GPVI agonist convu
phospho-antibodies, as indicated on the left, and anti-β-actin was used for equal loading contr
Results are the mean ± SD of three different experiments. *** = p b 0.005.platelets. Accurate quantitative analysis revealed that, as for the tyrosine
kinase Syk, phosphorylation of Akt was slightly increased in the absence
of c-Cbl. These results clearly demonstrate that Pyk2-mediated activation
of PI3Kβ in integrin α2β1 signaling does not require c-Cbl.
3.2. PI3Kβ activation by GPVI does not require Pyk2
Previous works by our group and others have demonstrated that
PI3Kβ plays amaster role in platelet activation by GPVI, but the implica-
tion of Pyk2 and c-Cbl has not been characterized [9,10]. In the present
study, we used CRP or convulxin as a selective GPVI agonist.We demon-
strated that, in addition to Ser473, also phosphorylation on Thr308 of
Akt was completely undetectable in platelets from mice expressing a
catalytically inactive form of PI3Kβ (Fig. 2A). However, in contrast to
what was observed upon integrin recruitment, CRP-induced phosphor-
ylation of Akt on both Ser473 and Thr308 occurred normally in platelets
lacking the tyrosine kinase Pyk2 (Fig. 2B), indicating that PI3Kβ activa-
tion downstream of GPVI is Pyk2-independent. Since CRP stimulation
was performed in a platelet suspension, while integrin engagement
required platelet adhesion to an immobilized ligand,we veriﬁedwheth-
er the different implication of Pyk2 in PI3Kβ activation could reﬂect the
different experimental setting. We thus analyzed Akt phosphorylation
in wild type and Pyk2-deﬁcient platelets upon adhesion to immobilized
CRP for 30 and 60min.We found that, even in this condition, ligation of
GPVI triggered Akt phosphorylation on Ser473 and Thr308 was compa-
rable in wild-type and Pyk2-deﬁcient platelets (Fig. 2C).
c-Cbl has been reported to be tyrosine phosphorylated upon GPVI
recruitment by a SFK- and Syk-dependent mechanism [26]. We there-
fore investigated the role of Pyk2 in c-Cbl phosphorylation downstream
of GPVI. Fig. 3A shows that c-Cbl phosphorylation in CRP-stimulated
platelets occurred normally in Pyk2-deﬁcient platelets, indicating that
this event is independent of Pyk2. Moreover, coimmunoprecipitation
experiments failed to detect any association of c-Cbl with the p852-deﬁcient (Pyk2KO) plateletswere stimulatedwith 0.5 μg/ml CRP for the indicated times.
y immunoblottingwith the anti-phosphotyrosine antibody (upper panel). Themembrane
oprecipitation. Quantitative analysis of c-Cbl phosphorylation from three different exper-
are themean ± SD of three different experiments. (B) Platelets fromwild type (WT) and
regulatory subunit of PI3K was immunoprecipitated. As positive control, p85 was
lotting analysis was performed with anti-c-Cbl and anti-p85 antibodies, as indicated on
tical results. (C) Analysis of Syk(Tyr525/526) and Akt(Ser473) phosphorylation in wild
lxin (100 ng/ml) for the indicated times. Immunoblotting was performed with speciﬁc
ol. Quantiﬁcation of Syk and Akt phosphorylation is reported is (ii) and (iii), respectively.
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Importantly, GPVI-induced phosphorylation of Akt occurred normally in
platelets from c-Cbl knockout mice (Fig. 3C). In agreement with previous
ﬁndings indicating that c-Cbl is a negative regulator of GPVI signaling [26],
Fig. 3C shows a strong potentiation of Syk phosphorylation in the absence
of c-Cbl, which, however, did not impact on PI3Kβ activation and Akt
phosphorylation (Fig. 3C). Altogether these results demonstrate that,
differently than for integrin signaling, neither c-Cbl nor Pyk2 contributes
to PI3Kβ regulation by GPVI.Fig. 4.Pyk2 is downstreamof PI3Kβ inGPVI signaling. (A) Platelets fromwild type (WT), PI3KβKD
on Tyr402was evaluated by immunoblottingwith a speciﬁc phospho-antibody, and the expression
of Pyk2 phosphorylation in wild type (black bars) PI3KβKD (gray bars) and PI3KγKD (white bars
(B) Wild type murine platelets were preincubated with PP2 (10 μM, 10 min), BAPTA-AM (10 μ
Expression and phosphorylation of Pyk2 on Tyr402was evaluated by immunoblotting using the an
titative analysis (mean ± SD) of three different experiments is reported in (ii). *** = p b 0.005. (
stimulatedwith 0.5 μg/ml CRP for increasing timeswas performedwith immunoblottingwith an a
iﬁed by immunoblotting with a speciﬁc antibody, as indicated on the right. A representative immu
reported in (ii) as themean±SD. ***=p b 0.005. (D) Platelets fromwild type (WT), PI3KβKD and
was immunoprecipitated and analyzed by immunoblottingwith anti-phosphotyrosine antibody fo
is representative of three different experiments. (E) Intracellular Ca2+ concentration was mea
100 ng/ml convulxin in the presence of extracellular EGTA. Results are the mean ± SD of three d3.3. Pyk2 is activated downstream of PI3Kβ in GPVI signaling
Since Pyk2 deﬁcient platelets aggregate normally upon GPVI stimula-
tion [21], we questioned whether Pyk2 was actually activated by CRP.
Fig. 4A shows that phosphorylation of Pyk2 on Tyr402, an autophosphor-
ylation site and a marker of its activation [27], is stimulated by CRP in a
time–dependent manner. Interestingly, activation of Pyk2 was impaired
in platelets expressing a catalytically inactive form of PI3Kβ, but was not
altered upon genetic ablation of PI3Kγ catalytic activity. These resultsor PI3KγKDmicewere stimulatedwith 0.5 μg/ml CRP for 0 to 10min. Phosphorylation of Pyk2
of Pyk2was veriﬁedwith an anti-Pyk2 antibody, as indicated on the right (i). Quantiﬁcation
) platelets are reported in (ii) as mean ± SD of three different experiments. *** = p b 0.005.
M, 15 min), or U73122 (10 μM, 3 min), and then stimulated with 0.5 μg/ml CRP for 5 min.
tibodies indicated on the right. A representative immunoblot is reported in (i), and the quan-
C) Analysis of pleckstrin phosphorylation in platelets fromWT, PI3KβKD and PI3KγKD mice
nti-(phospho)PKC substrates (P-PKCsub), and the amount of pleckstrin in each lanewas ver-
noblot is reported in (i), and quantiﬁcation of the results from three different experiments is
PI3KγKDmicewere left untreated or stimulatedwith 100 ng/ml convulxin for 5min. PLCγ2
llowing by reprobingwith anti-PLCγ2 antibody, as indicated on the right. The reported ﬁgure
sured in Fura-2-loaded platelets from wild type (WT) and PI3KβKD mice stimulated with
ifferent determinations. * = p b 0.05.
Fig. 4 (continued).
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PI3Kβ.
It is known that Pyk2 can be activated by both SFK and Ca2+ [27].
Fig. 4B shows that CRP-induced Pyk2 activation was completely abro-
gated in platelets treated with the Src family kinase (SFK) inhibitor
PP2, or incubated with the intracellular Ca2+ chelator BAPTA-AM.
Upon activation of GPVI, intracellular Ca2+ increase is consequent to
activation of PLCγ2, which is stimulated through SFK-mediated phos-
phorylation [5]. By using the PLC inhibitor U73122, we found that
CRP-induced Pyk2 phosphorylation was downstream of PLCγ2 activa-
tion (Fig. 4B). Since it is known that the lipid products of PI3K are
required for efﬁcient activation of PLCγ2, we evaluated PLCγ2 activity
bymeasuring the phosphorylation of pleckstrin, themain PKC substrate
and a very well standardized marker for PLC activation [28]. Fig. 4C
shows that CRP-induced pleckstrin phosphorylation was completely
suppressed in platelets from PI3KβKDmice, butwas normal in PI3KγKD
platelets. Moreover, we observed that tyrosine phosphorylation of
PLCγ2 in murine platelets stimulated with the GPVI agonist convulxin
was strongly inhibited in the absence of PI3Kβ, but not PI3Kγ, catalytic
activity (Fig. 4D). Finally, to conﬁrm the regulation of PLCγ2 activationby PI3Kβ downstream of GPVI, we compared the release of Ca2+ from
intracellular stores in control and PI3KβKD platelets. Fig. 4E shows
that catalytic inactivation of PI3Kβ virtually abrogated the convulxin-
stimulated increase of cytosolic Ca2+. These results indicate that
PI3Kβ is absolutely required for PLCγ2 activation downstream of GPVI
and that PLCγ2-mediated intracellular Ca2+ increase links PI3Kβ to
Pyk2 activation.
Finally, we sought to verify whether Pyk2 and PLCγ2 regulation by
PI3Kβ observed in murine platelets could also be translated to humans.
Fig. 5A shows that Pyk2 phosphorylation in human platelets stimulated
with convulxin was signiﬁcantly inhibited by wortmannin and by the
PI3Kβ selective inhibitor TGX-221, but not by the PI3Kγ inhibitor
AS252424. Moreover, TGX-221 and wortmannin, but not AS252424,
caused a strong, albeit not complete, inhibition of pleckstrin phosphor-
ylation induced by convulxin in human platelets (Fig. 5B), as well as
mouse platelets (data not shown). Similarly, PI3Kβ inhibition by TGX-
221 signiﬁcantly reduced the intracellular Ca2+ release in convulxin-
stimulated human platelets (Fig. 5C). Altogether, these results conﬁrm
that also in human platelets PI3Kβ regulates PLCγ2 activity and Pyk2
phosphorylation downstream of GPVI stimulation.
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PI3Kβ is recognized to play a crucial role in platelet activation, and is
predominantly involved in platelet responses triggered by integrin
outside-in signaling and GPVI engagement [9,10]. We have recently
described a signaling pathway activated downstream of integrin αIIbβ3,
that links the tyrosine kinase Pyk2 and the adaptor protein c-Cbl to
PI3Kβ stimulation. In the present work, we demonstrate that this path-
way appears restricted to integrin αIIbβ3, as it is not shared by other
platelet receptors that stimulate PI3Kβ. In particular, we compared theFig. 5. Regulation of Pyk2 and PLCγ2 by PI3Kβ in human platelets. Human platelets were treate
ume of DMSO (none) for 10min and then stimulatedwith 100 ng/ml convulxin for 5 min. A. Im
anti-Pyk2(Tyr402) antibody and equal loading control was performed by reprobing with anti-
(i) and quantiﬁcation of phosphorylation, expressed asmean±SDof three different experimen
with immunoblotting with an anti-(phospho)PKC substrates (P-PKCsub), and the amount of pl
on the right. A representative immunoblot is reported in (i), and quantiﬁcation of the resul
(C) Intracellular Ca2+ concentration was measured in Fura-2-AM-loaded human platelets i
100 ng/ml convulxin. Results are the mean ± SD of three different determinations. ** = p b 0.mechanisms for PI3Kβ activation downstream of the two major collagen
receptors in platelets: integrin α2β1 and GPVI. We conﬁrmed that PI3Kβ
activation by integrin α2β1 is regulated by Pyk2, but does not involve c-
Cbl, as previously hypothesized. Moreover, we demonstrated that in
platelets stimulated with GVI ligands, PI3Kβ does not lie downstream
but, rather, upstream of Pyk2 phosphorylation. Therefore, our results
demonstrate the existence of different mechanisms regulating PI3Kβ by
integrins or by GPVI in platelets.
It is generally accepted that the p110 catalytic subunits of class IA
PI3K members, including PI3Kβ, are maintained in an inactive statedwith 0.5 μM TGX-211, 0.5 μMAS252424, 100 nMwortmannin of with an equivalent vol-
munoblotting analysis of Pyk2 phosphorylation was performed onwhole cell lysates with
Pyk2 antibody, as indicated on the right. A representative immunoblotting is reported in
ts is reported in (ii). *= p b 0.05. (B) Analysis of pleckstrin phosphorylationwas performed
eckstrin in each lanewas veriﬁed by immunoblotting with a speciﬁc antibody, as indicated
ts from three different experiments is reported in (ii), as the mean ± SD. * = p b 0.05.
ncubated with DMSO (none) or 0.5 μM TGX-221 for 10 min, and then stimulated with
01.
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subunit, mainly p85, and that activation occurs when this constitutive
inhibition is relieved by binding of tyrosine phosphorylated proteins
to the SH2 domain of p85. Activated growth factor receptors, cytosolic
tyrosine kinases, as well as phosphorylated adaptor proteins can inter-
act with p85 and cause the activation of p110 catalytic subunit [14].
Among these, the adaptor protein c-Cbl is a known binding partner
and activator of PI3K [29–34], and has been shown to associate with
PI3K in integrinαIIbβ3 outside-in signaling, and to be tyrosine phosphor-
ylated by Pyk2 (15). Here we demonstrated that upon integrin α2β1 en-
gagement c-Cbl interacts with PI3K but is not tyrosine-phosphorylated.
Moreover, integrin α2β1-mediated phosphorylation of Akt on both
Ser473 and Thr308 occurred normally in platelets lacking c-Cbl. We con-
clude that, differently from what proposed for integrin αIIbβ3 [15], Pyk2
is important for PI3Kβ activation by integrin α2β1, but this effect is not
mediated by c-Cbl.
In addition to integrin α2β1, GPVI is an important platelet collagen
receptor essential for thrombus formation,which relies on PI3Kβ activa-
tion to stimulate platelet responses. In the present work we have dem-
onstrated that the regulation of PI3Kβ by Pyk2 is restricted to integrin
α2β1, and that Pyk2 is not required for PI3Kβ activation upon GPVI
stimulation. Moreover, platelet stimulation by CRP, a speciﬁc GPVI
ligand, did not cause the association of c-Cbl with the p85 regulatory
subunit, and GPVI-promoted phosphorylation of c-Cbl was not mediat-
ed by Pyk2. In addition, phosphorylation of Akt downstream of GPVI
occurred normally in c-Cbl-deﬁcient platelets. Therefore, the signaling
pathways associated with PI3Kβ activation upon collagen binding to
integrin α2β1 are not recapitulated by collagen stimulation of GPVI.
Previous works have demonstrated that c-Cbl negatively regulates
GPVI responses [26]. Althoughwe conﬁrmed the hyperphosphorylation
of Syk in c-Cbl deﬁcient platelets, phosphorylation of Akt was not signif-
icantly increased, indicating that c-Cbl does not target the PI3K pathway
to limit platelet activation byGPVI. Platelets also express Cbl-b, a second
member of the Cbl family, that, in differently to c-Cbl, has been implicat-
ed in GPVI-mediated platelets activation [32]. The antibody used in the
present study is speciﬁc for c-Cbl as indicated in the data sheet, and thus
whether or not Cbl-b may contribute to PI3Kβ activation and Akt phos-
phorylation by GPVI or by integrin α2β1 remains to be established.
The evidence that Pyk2 in not involved in PI3Kβ regulation down-
stream of GPVI is consistent with previous observations showing that
while genetic ablation or enzymatic inhibition of PI3Kβ dramatically
prevents GPVI-induced platelet aggregation, secretion and ﬁbrinogen
binding, Pyk2-deﬁcient platelets aggregate normally in response to
GPVI stimulation, and neither secretion nor integrin αIIbβ3 activation
were signiﬁcantly impaired [9,21]. Nevertheless, we demonstrated
here that a functional link exists between Pyk2 and PI3Kβ in GPVI
signaling, since Pyk2 activation has been found to lie downstream of
PI3Kβ activity. In CRP-stimulated platelets, Pyk2 activation is completely
dependent on intracellular Ca2+, and we propose that its regulation by
PI3Kβ is secondary to the regulation of PLCγ2, which is responsible for in-
tracellular Ca2+ increase. It is well known that the 3-phosphoinositides
are required for efﬁcient stimulation of the γ family of PLC, as they favor
membrane translocation [33], and PI3K inhibitors have been reported to
reduce PLCγ2 activity in GPVI-stimulated platelets [34]. Here we show
that in platelets from mice expressing a catalytically inactive form of
PI3Kβ, but not PI3Kγ, PLCγ2 phosphorylation is prevented and its activa-
tion is suppressed, as demonstrated by the lack of PKC-directed protein
phosphorylation and by the reduced release of Ca2+ from internal stores.
Importantly, using selective and speciﬁc pharmacological inhibitors, we
found that the regulation of Pyk2 and PLCγ2 by PI3Kβ also occurs in
human platelets. These observations provide important hints to under-
stand the mechanism for the previously reported crucial role of PI3Kβ in
GPVI-mediated platelet activation and aggregation.
In conclusion, our study recognizes that multiple mechanisms are
indeed involved in PI3Kβ regulation in platelets, and identiﬁes Pyk2 as
a regulator of PI3Kβ exclusively downstream of integrin ligation, butnot upon GPVI stimulation. Since PI3Kβ is currently regarded as a prom-
ising target for anti-platelet drugs, our results suggest novel strategies
to differentially target PI3Kβ activity in selected contexts of platelet
activation.
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